Journals / Turkish Journal of Anaesthesiology and Reanimation / 2015 / Cilt: 43 - Sayı: 5

Synthetic Cannabinoid ‘Bonzai’ Intoxication: Six Case Series

Sentetik Kannabinoid ‘Bonzai’ İntoksikasyonu: Altı Olgu Serisi

Pages
347–351
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this study, we report the difficulties in the clinical course, treatment and man- agement of six patients that had a use history of bonzai although it was not detected in blood in a short period of time in the intensive care unit

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In the language of the streets, ‘bonzai’, known as ‘1-naphthalenyl of methanol’, also known as JWH-18 group, is a drug belonging to the group of synthetic cannabinoids.
📊
Key Findings & Data:At the beginning of 2004, it started to be sold on the internet and it is seen that private markets.
💡
Conclusion & Impact:In this study, we report the difficulties in the clinical course, treatment and man- agement of six patients that had a use history of bonzai although it was not detected in blood in a short period of time in the intensive care unit
🔬Design:Research Article
📍Scope:2004 Verileri
⚙️Variables:Domain Parameters

Abstract

In the language of the streets, ‘bonzai’, known as ‘1-naphthalenyl of methanol’, also known as JWH-18 group, is a drug belonging to the group of synthetic cannabinoids. At the beginning of 2004, it started to be sold on the internet and it is seen that private markets. It has structurally similar chemical characteristics as delta 9-tetrahydrocannabinol (THC), the active substance in marijua- na. In 2013, in a study conducted by the European Monitoring Centre of Drugs and Drug Addiction (EMCDDA), 102 varieties of synthetic cannabinoids were identified; however, more than 200 substances have been reported since 1997. In this study, we report the difficulties in the clinical course, treatment and man- agement of six patients that had a use history of bonzai although it was not detected in blood in a short period of time in the intensive care unit

Özet

Sokak dilinde "bonzai" olarak bilinen "1-naftalenil methanon", diğer adıyla JWH-18 grubu, sentetik kannabinoid grubuna ait bir uyuşturucu maddedir. 2004 yılı başlarında internet üzerinde ve özel marketlerde satışına başlandığı görülmektedir. Esrarın etken maddesi olan delta 9-tetrahidrokannabinol (THC) ile kimyasal olarak benzer bir yapısal özellik gösterir. 2013 yılında EMCDDA (European Monitoring Centre of Drugs and Drug Addiction) tarafından yapılan bir çalışmada 102 çeşit sentetik kannobino- id madde tespit edilmekle beraber 1997 yılından bu yana 200'ü aşkın madde bildirilmektedir. Biz bu vaka takdiminde; kısa bir zaman dilimi içerisinde yoğun bakım servisinde takip ettiğimiz kullanım öyküsü olmasına rağmen kanda saptanamamış bonzai almış 6 hastanın, klinik seyrini, tedavi yönetimini ve tanı koymak- ta yaşanan güçlükleri tartışmaya çalıştık

🔖

Cite This Article

ERGÜL, D. F., EKEMEN, S., YELKEN, B. B. (2015). Synthetic Cannabinoid ‘Bonzai’ Intoxication: Six Case Series. Turkish Journal of Anaesthesiology and Reanimation, Cilt: 43 - Sayı: 5, 347–351. https://ajindex.com/articles/370347

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Fattore L, Fratta W. Beyond THC: The New Generation of Cannabinoid Designer Drugs. Front Behav Neurosci 2011; 5: 60. [CrossRef] 2. Davidson C. New psychoactive substances. Prog Neuropsychopharmacol Biol Psychiatry 2012; 39: 219-20. [CrossRef] 3. Huffman JW, Dai D, Martin BR, Compton DR. Design, synthesis and pharmacology of cannabimimetic indoles. Bioorg Med Chem Lett 1994; 4: 563-6. [CrossRef] 4. Schneir AB, Cullen J, Ly BT. “Spice” girls: Synthetic cannabinoid intoxication. J Emerg Med 2011; 40: 296-9. [CrossRef] 5. Harris CR, Brown A. Synthetic cannabinoid intoxication: a case series and review. J Emerg Med 2013; 44: 360-6. [CrossRef] 6. Arnold C. The new danger of synthetic drugs. Lancet 2013; 382: 15-6. [CrossRef] 7. Bhanushali GK, Jain G, Fatima H, Leisch LJ, Thornley-Brown D. AKI associated with synthetic cannabinoids: a case series. Clin J Am Soc Nephrol 2013; 8: 523-6. [CrossRef] 8. UNODC, Synthetic cannabinoids in herbal products. United Nations Office on Drugs and Crime, 2011. Last accessed February 19, 2013. 9. Möller I, Wintermeyer A, Bender K, Jübner M, Thomas A, Krug O, et al. Screening for the synthetic cannabinoid JWH- 018 and its major metabolites in human doping controls. Drug Test Anal 2011; 3: 609-20. [CrossRef] 10. Çevik SE, Taşyürek T, Güneysel O. Intralipid emulsion treatment as an antidote in lipophilic drug intoxications: a case series. Am J Emerg Med 2014; 32: 1103-8. [CrossRef]